Comparative effectiveness of concurrent chemoradiotherapy versus EGFR‐tyrosine kinase inhibitors for the treatment of clinical stage IIIb lung adenocarcinoma patients with mutant EGFR

BACKGROUND: The standard of care for fit locally advanced non‐small cell lung cancer (NSCLC) patients is concurrent chemoradiotherapy (CCRT). However, in a subset of patients with lung adenocarcinoma with mutant EGFR (LA‐mEGFR), the role of EGFR‐tyrosine kinase inhibitors (TKIs) is not clear. We com...

Descripción completa

Detalles Bibliográficos
Autores principales: Hsia, Te‐Chun, Liang, Ji‐An, Li, Chia‐Chin, Chien, Chun‐Ru
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2018
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6209772/
https://www.ncbi.nlm.nih.gov/pubmed/30152040
http://dx.doi.org/10.1111/1759-7714.12847

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6209772/
https://www.ncbi.nlm.nih.gov/pubmed/30152040
http://dx.doi.org/10.1111/1759-7714.12847

Ejemplares similares